Processing

Please wait...

Settings

Settings

1. WO1996005222 - PURIFICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING TYPE G BOTULINUM NEUROTOXIN

Publication Number WO/1996/005222
Publication Date 22.02.1996
International Application No. PCT/US1995/007932
International Filing Date 21.06.1995
Chapter 2 Demand Filed 05.03.1996
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/33 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
Y02A 50/469
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
46Medical treatment of waterborne diseases characterized by the agent
468The waterborne disease being caused by a bacteria
469the bacteria being clostridium botulinum, i.e. Botulism
Y10S 435/842
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
435Chemistry: molecular biology and microbiology
8215Microorganisms
822using bacteria or actinomycetales
842Clostridium
Y10S 530/825
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
530Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
82Proteins from microorganisms
825Bacteria
Applicants
  • WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365 Madison, WI 53707-7365, US
Inventors
  • JOHNSON, Eric, A.; US
  • SUGIYAMA, Hiroshi; US
  • MALIZIO, Carl, J.; US
Agents
  • HAAS, George, E. ; Quarles & Brady 411 East Wisconsin Avenue Milwaukee, WI 53202, US
Priority Data
08/287,35008.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PURIFICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING TYPE G BOTULINUM NEUROTOXIN
(FR) PROCEDE DE PURIFICATION ET COMPOSITIONS PHARMACEUTIQUES CONTENANT LA NEUROTOXINE BOTULINIQUE DE TYPE G
Abstract
(EN)
The isolation and purification of type G botulinum neurotoxin and complexes thereof is disclosed. Compositions containing the type G neurotoxin and the preparation of a type G toxoid are also disclosed.
(FR)
L'invention se rapporte à l'isolement et à la purification de la neurotoxine botulinique de type G et à ses complexes, et également aux compositions contenant la neurotoxine de type G et à la préparation d'une antitoxine de type G.
Also published as
Latest bibliographic data on file with the International Bureau